Anavex Life Sciences Corp. (AVXL): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVXL Stock Price Chart Interactive Chart >
AVXL Price/Volume Stats
| Current price | $9.71 | 52-week high | $31.50 |
| Prev. close | $9.06 | 52-week low | $7.13 |
| Day low | $8.84 | Volume | 995,400 |
| Day high | $9.77 | Avg. volume | 1,072,890 |
| 50-day MA | $10.36 | Dividend yield | N/A |
| 200-day MA | $15.01 | Market Cap | 751.64M |
Anavex Life Sciences Corp. (AVXL) Company Bio
Anavex Life Sciences Corporation is engaged in the discovery and development of drugs for the treatment of Alzheimers disease, central nervous system diseases, and pain and various cancers. The company was founded in 2006 and is based in New York, New York.
Latest AVXL News From Around the Web
Below are the latest news stories about Anavex Life Sciences Corp that investors may wish to consider to help them evaluate AVXL as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Applied DNA Sciences (APDN), Glaukos (GKOS) and Anavex Life Sciences (AVXL)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Applied DNA Sciences (APDN – Research Report), Glaukos (GKOS – Research Report) and Anavex Life Sciences (AVXL – Research Report) with bullish sentiments. Applied DNA Sciences (APDN) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Applied DNA Sciences, with a price target of $6.00. The company's shares closed last Thursday at $3.11, equals to its 52-week low of $3.11. According to TipRanks. |
BTIG Thinks Anavex Life Sciences’ Stock is Going to RecoverIn a report released yesterday, Yun Zhong from BTIG reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $35.00. The company's shares closed last Wednesday at $11.74, close to its 52-week low of $9.93. According to TipRanks.com, Zhong is ranked 0 out of 5 stars with an average return of -22.8% and a 16.2% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Sarepta Therapeutics, and Sio Gene Therapies. Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $31.50, which is a 180.2% upside from current levels. |
Anavex Life Sciences (AVXL) Q1 2022 Earnings Call TranscriptAVXL earnings call for the period ending December 31, 2021. |
Anavex Life Sciences Corp. (AVXL) Is A Possible Investment At Current LevelsAnavex Life Sciences Corp. (NASDAQ:AVXL) price on Wednesday, February 09, rose 5.77% above its previous days close as an upside momentum from buyers pushed the stocks value to $11.74. A look at the stocks price movement, the close in the last trading session was $11.10. The beta value (5-Year monthly) was 0.61. Turning to its Anavex Life Sciences Corp. (AVXL) Is A Possible Investment At Current Levels Read More » |
Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceNEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the virtual 11 th Annual SVB Leerink Global Healthcare Conference and present on Wednesday, February 16 at 3 pm ET. |
AVXL Price Returns
| 1-mo | 8.01% |
| 3-mo | -9.59% |
| 6-mo | -52.50% |
| 1-year | -22.01% |
| 3-year | 217.32% |
| 5-year | 65.14% |
| YTD | -44.00% |
| 2021 | 221.11% |
| 2020 | 108.49% |
| 2019 | 66.03% |
| 2018 | -51.55% |
| 2017 | -18.69% |
Loading social stream, please wait...